Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nigopram
- Development stage
- Unknown
- Lead developer
- SNIG Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nigopram is a branded generic small molecule antidepressant containing escitalopram oxalate, developed and marketed by SNIG Pharmaceuticals Pvt Ltd. It belongs to the selective serotonin reuptake inhibitor (SSRI) class of medications. Nigopram is indicated for the treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder. It functions by binding to the serotonin transporter (SERT) in the central nervous system, effectively blocking the reabsorption of serotonin into neurons. This action increases the extracellular level of serotonin, thereby enhancing serotonergic neurotransmission and improving mood and anxiety symptoms. The drug is available in oral tablet form and is part of SNIG Pharma's CNS therapeutic segment.
- Brand names
- Nigopram
- Other names
- escitalopram oxalate
02
Targets
GABRR (GABA-A receptor subunit rho)SERT (Sodium-dependent serotonin transporter)OCT1 (Organic cation transporter 1)
Beyond the preview
Go deeper on Nigopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nigopram.